Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets

Yingzhou Shi, Hang Dong, Shiwei Sun, Xiaoqin Wu, Jiansong Fang, Jianbo Zhao, Junming Han, Zongyue Li, Huixiao Wu, Luna Liu, Wanhong Wu, Yang Tian, Guandou Yuan, Xiude Fan, Chao Xu

Clin Mol Hepatol. 2024;30(1):80-97. Published online December 7, 2023

DOI: https://doi.org/10.3350/cmh.2023.0343

View: 3004 Download: 155 Crossref: 1

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Roles of the complement system in alcohol-induced liver disease

Yi Zhou, Guandou Yuan, Fudi Zhong, Songqing He

Clin Mol Hepatol. 2020;26(4):677-685. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0094

View: 6544 Download: 140 Web of Science: 9 Crossref: 11

Correspondence

Reply to: “Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization”

Yingzhou Shi, Guandou Yuan, Xiude Fan, Chao Xu

Received April 16, 2024 Accepted April 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0266 [Accepted]

View: 131 Download: 6

1 |

Viewed By 5375	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5336	MAFLD: How is it different from NAFLD?
Viewed By 5224	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3902	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3868	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Search